Tenofovir anhydrous
As of the edition of 20 October 2026, Tenofovir anhydrous is a small molecule: marketed, first approved in 2002 (CH).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2004
- Kind
- Small molecule
- Brand name
- Viread
- First approved
- 6 December 2002 (CH)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- Merck & Co.; 4 holders in all
- Registered trials
- 167, 20 stopped early
- Disease areas
- Infections; Immune system; Urinary and reproductive; Digestive system; Blood and lymph; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 29 | 20 | 2 | 2 |
| Phase 1 | 33 | 29 | 0 | 2 |
| Phase 2 | 33 | 21 | 0 | 10 |
| Phase 3 | 24 | 18 | 0 | 1 |
| Phase 4 | 48 | 32 | 1 | 5 |
| All trials | 167 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Japan Tobacco | Applicant | 2004 to now |
| Merck & Co. | Later holder and Lead sponsor of trials | 2005 to now |
| Johnson & Johnson | Applicant and Lead sponsor of trials | 2008 to now |